We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ViroLogic has announced that it had entered into an agreement with AstraZeneca
to conduct a cancer biomarker study with application to Iressa, AstraZeneca's
selective epidermal growth factor receptor kinase inhibitor.
Gene Network Sciences has signed a drug development contract with Johnson &
Johnson Pharmaceutical Research & Development (J&JPRD), a division of
Janssen Pharmaceutica N.V.
Acting FDA Commissioner Lester Crawford believes the science is available for
the FDA to move forward on follow-on biologic products, but he told a recent
industry conference that the FDA still has many kinks to work out on the regulatory
front.
Mylan Laboratories has officially closed the door on its planned merger with
King Pharmaceuticals, announcing that it is not moving forward with the $4 billion
deal.
Biogen Idec and Elan have suspended sales
of their multiple sclerosis (MS) drug Tysabri following reports that the product
might have contributed to a pair of serious adverse events, including one patient
death.
At the request of the FDA, U.S. marshals have seized more than $13,000 worth
of adulterated and misbranded dietary supplements from a Pennsylvania firm believed
to be marketing products containing ephedrine alkaloids.
Biovail has reported that the Securities and Exchange Commission has launched
a formal investigation into the Toronto-based drug maker's accounting practices.
Taro Pharmaceutical Industries and its subsidiaries reported that the company
has entered into multiyear agreements to divest its OTC ElixSure and Kerasal
products in North America to Alterna.